Pharmacokinetics of ropivacaine after intraperitoneal instillation in anaesthetized dogs: a randomized clinical trial

Title (eng)
Pharmacokinetics of ropivacaine after intraperitoneal instillation in anaesthetized dogs: a randomized clinical trial
Author
Natali Verdier
Author
Karin Hummel
Author
Valentin Al-Jalali
Author
Svenja Claaßen
Author
Pablo A. Donati
Author
Diego A. Portela
Author
Ebrahim Razzazi-Fazeli
Author
Martina Mosing
Abstract (eng)
Objective To evaluate the pharmacokinetics of two doses of intraperitoneal ropivacaine in anaesthetized dogs. Study design Randomized clinical trial. Animals A total of 20 dogs undergoing ovariectomy/ovariohysterectomy. Methods Dogs were anaesthetized and randomized to be given 1 (group R1) or 3 (group R3) mg kg-1 of ropivacaine intraperitoneally, diluted with 0.9% NaCl to a total volume of 0.8 mL kg-1. Before abdominal wall closure, solution aliquots were instilled over the ovarian pedicles and, if applicable, the uterine stump. Venous blood was sampled 2 minutes before and 5, 10, 15, 30, 45, 60, 120 and 240 minutes after instillation. Cardiovascular signs of toxicity were noted. Plasma concentrations of free and total ropivacaine were measured using ultrahigh-performance liquid chromatography–mass spectrometry. Plasma protein binding (PPB) was determined by rapid equilibrium dialysis. Pharmacokinetic parameters were derived by a noncompartmental analysis, and the maximum total and free ropivacaine plasma concentrations (Cmax) were compared between groups using an independent samples t-test. Data are presented as mean or median (95% confidence intervals). Significance was set at p < 0.05. Results One dog in R3 was excluded. Total ropivacaine Cmax values were 0.27 (0.21–0.33) and 0.67 (0.43–0.92) mg L-1 at 15 (8.64–30.35) and 5 (1.77–8.23) minutes (Tmax) for R1 and R3, respectively, and different between groups (p = 0.005). Free ropivacaine Cmax values were 0.02 (0.02–0.03) and 0.06 (0.03–0.09) mg L-1 at 10 (4.67–15.32) and 5 (0–19.13) minutes (Tmax) for R1 and R3, respectively, and Cmax was different between groups (p = 0.015). Median ropivacaine PPB for all dogs was 92.5% (89.7–95.2%). No signs of cardiovascular toxicity were noted. Conclusions and clinical relevance Although R3 had a greater total and free ropivacaine Cmax than R1, Cmax remained below toxic levels in all dogs.
Keywords (eng)
CanineIntraperitonealLocal AnasthesiaPharmacokineticsRopivacaineToxicity
Type (eng)
journal article
Language
[eng]
Persistent identifier
https://phaidra.vetmeduni.ac.at/o:5364
DOI
10.1016/j.vaa.2025.10.002
Is in series
Title (eng)
Veterinary Anaesthesia and Analgesia
Volume
53
Issue
2
ISSN
1467-2987
Issued
2026
Number of pages
10
Publication
Elsevier
Version type (eng)
version of record (published version)
Date issued
2026
Access rights (eng)
open access
License
CC BY 4.0 International
Rights statement (eng)
© 2025 The Author(s)